Michael Hayden
CEO
Claimed by owner Prilenia Neurotherapeutics
Former names: Prilenia Therapeutics, Prilenia
Treatments for Neurodegenerative and Neurodevelopmental Disorders
Prilenia Neurotherapeutics
www.newswise.com
•
May 25, 2022
Prilenia announces publication of data elucidating a mechanism for neuroprotective potential of pridopidine
www.businesswire.com
•
Apr 12, 2022
SV Health Investors Joins Prilenia Series B as the Company Prepares for ALS and HD Data Readouts in the Next 12 Months
www.finsmes.com
•
Nov 4, 2021
Prilenia Therapeutics Raises $43M in Series B Funding - FinSMEs
www.businesswire.com
•
Jan 28, 2021
Prilenia Enrolls First Subject in Europe in its PROOF-HD Phase 3 Clinical Trial for Huntington's Disease
www.businesswire.com
•
Jan 8, 2021
Prilenia Announces First Patient Enrolled for Pridopidine Phase 2/3 Platform Trial for ALS
www.businesswire.com
•
Oct 27, 2020
Prilenia Enrolls First Patients Into its PROOF-HD Phase 3 Clinical Trial for Huntington's Disease in the United States
en.globes.co.il
•
Jun 3, 2020
Prilenia Therapeutics raises $62.5m, names Michael Hayden CEO
www.businesswire.com
•
Sep 8, 2019
Prilenia's Pridopidine Chosen to Participate in the First ALS Platform Trial
About
Prilenia Neurotherapeutics is a clinical-stage biotechnology company and the developer of pridopidine, a highly selective sigma-1 receptor agonist with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children.
Pridopidine has been shown to maintain functional capacity in early Huntington's disease (HD) patients, as measured by total functional capacity. Furthermore, it was recently selected from an international competition of over 30 potential therapeutics for inclusion in an ALS platform trial led by the Healey Center for ALS at Massachusetts General Hospital.
Pridopidine is currently in late-stage clinical development for HD and ALS. In the face of compelling results, these trials could potentially lead to the registration of pridopidine for these indications.
Pridopidine has been shown to maintain functional capacity in early Huntington's disease (HD) patients, as measured by total functional capacity. Furthermore, it was recently selected from an international competition of over 30 potential therapeutics for inclusion in an ALS platform trial led by the Healey Center for ALS at Massachusetts General Hospital.
Pridopidine is currently in late-stage clinical development for HD and ALS. In the face of compelling results, these trials could potentially lead to the registration of pridopidine for these indications.
Employees
Product stage
Primary Sector
Life Sciences & HealthTech
Products
Pridopidine
Geographic markets
-
News
(8)
www.newswise.com
•
May 25, 2022
Prilenia announces publication of data elucidating a mechanism for neuroprotective potential of pridopidine
www.businesswire.com
•
Apr 12, 2022
SV Health Investors Joins Prilenia Series B as the Company Prepares for ALS and HD Data Readouts in the Next 12 Months
www.finsmes.com
•
Nov 4, 2021
Prilenia Therapeutics Raises $43M in Series B Funding - FinSMEs
www.businesswire.com
•
Jan 28, 2021
Prilenia Enrolls First Subject in Europe in its PROOF-HD Phase 3 Clinical Trial for Huntington's Disease
www.businesswire.com
•
Jan 8, 2021
Prilenia Announces First Patient Enrolled for Pridopidine Phase 2/3 Platform Trial for ALS
www.businesswire.com
•
Oct 27, 2020
Prilenia Enrolls First Patients Into its PROOF-HD Phase 3 Clinical Trial for Huntington's Disease in the United States
en.globes.co.il
•
Jun 3, 2020
Prilenia Therapeutics raises $62.5m, names Michael Hayden CEO
www.businesswire.com
•
Sep 8, 2019
Prilenia's Pridopidine Chosen to Participate in the First ALS Platform Trial
The Team
(5)
MH
EG
Elizabeth Gilad
Executive Assistant to the CEO & Office Manager
LBH
Limor Ben Har
COO
EB
Elena Berelovich
VP & Head of CMC
MG
Michal Geva
Head of Non-Clinical Development
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Company Lifecycle
Private Equity Funding
Undisclosed Round
$20M
1 Investors
$20M
A Round
$62.5M
Jun 2020
4 Investors
$62.5M
B Round
$43M
Nov 2021
7 Investors
$43M
B Round
$10M
Apr 2022
7 Investors
$10M
Media gallery
(0)Locations
Israel
Ha-Menofim St 10, Herzliya, Israel
Offices Abroad
Naarden, Netherlands
Locations
Israel
Ha-Menofim St 10, Herzliya, Israel
Offices Abroad
Naarden, Netherlands
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Smartlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,